MR. KARL FREDERICK POPP, R.PH.
Pharmacy at Coleman St, Chatham, NY

2006004, Mar 2, 2006

Aug 27, 2004

10/927493

Harold Meckler - Delmar NY, US
Karl Popp - Schodack Landing NY, US
Bingidimi Mobele - Altamont NY, US
Paul Isbester - Castleton NY, US
Bruce Elder - Wynantskill NY, US
Paul Vogt - Arlington Heights IL, US
Benjamin Littler - Mount Prospect IL, US
Stephen Eastham - Rexford NY, US
David Reed - Clifton Park NY, US
Luckner Ulysse - Albany NY, US
Michael Uttley - Delmar NY, US

A61K 31/16, C07C 233/24

564219000, 514630000

Processes for preparing an amine compound by catalytically hydrogenating a precursor nitrile compound. In a particular aspect, the present hydrogenation process occurs in a dipolar organic solvent in the presence of a palladium/carbon catalyst and a strong anhydrous protic acid. In a further aspect, the preferred embodiment relates to a process for deprotecting a compound to produce an amine compound. In yet a further aspect, the preferred embodiment relates to amine products produced by the present processes. These amine products may be used for a variety of purposes.

5525358, Jun 11, 1996

Apr 19, 1995

8/424051

Karl F. Popp - Schodack Landing NY

Schering-Plough Healthcare Products, Inc. - Memphis TN

A61K 4738, A61K 4732, A61K 910

424486

Gel film-forming flexible collodion compositions can be improved by including one or more topically acceptable polymers in an amount sufficient to increase the resilience of the film formed. Suitable polymers include polyalkylenes and (meth)acrylate homo- or copolymers. The compositions can further include salicylic acid and a topically acceptable crystallization inhibitor in an amount sufficient to suppress the crystallization of dissolved salicylic acid from the composition.

5433950, Jul 18, 1995

Apr 16, 1993

8/048818

Karl F. Popp - Schodack Landing NY

Schering-Plough Healthcare Products, Inc. - Memphis TN

A61K 4738, A61K 4732

424400

Film-forming flexible collodion compositions can be improved by including one or more topically acceptable polymers in an amount sufficient to increase the resilience of the film formed. Suitable polymers include polyalkylenes and (meth)acrylate homo- or copolymers. The compositions can further include salicylic acid and a topically acceptable crystallization inhibitor in an amount sufficient to suppress the crystallization of dissolved salicylic acid from the composition.

7186416, Mar 6, 2007

May 28, 2003

10/445487

Karl F. Popp - Schodack Landing NY, US
Edward R. Yuhas - Yonkers NY, US

Stiefel Laboratories, Inc. - Coral Gables FL

A61K 7/00, A61K 9/12, A61K 31/57

424401, 424 45, 424 7803, 424 7806

Novel compositions of matter comprising a foamable delivery system are provided. Novel methods for treating a disease, disorder, or condition using the novel compositions are further provided. Novel methods for making and delivering a foamable pharmaceutical composition are also provided. While the novel compositions and foamable drug delivery system may be utilized for administration of a wide variety of drugs to epithelial tissues, to treat a wide variety of diseases, disorders, or conditions, the inventive compositions and foamable drug delivery systems are particularly useful for the dermatological administration of corticosteroids and antifungal agents.

4420484, Dec 13, 1983

Nov 12, 1981

6/320754

William G. Gorman - East Greenbush NY
Karl F. Popp - Schodack Landing NY

Sterling Drug Inc. - New York NY

A61K 3155

424326

Basic amino or ammonium antimicrobial agent (especially bisbiguanide, quaternary ammonium salt and bispyridine)-polyethylene glycol ester surfactant-betaine and/or amine oxide surfactant antimicrobial skin cleansing compositions and method of use thereof are disclosed.

2010021, Aug 19, 2010

Apr 30, 2010

12/771074

Karl F. Popp - Schodack Landing NY, US

STIEFEL LABORATORIES, INC. - Coral Gables FL

A61K 31/7056, A61P 31/04, A61P 17/00, A61P 17/10

514 24

Topical compositions and methods of using same for treating skin disorders or conditions comprising a storage-stable mixture of a benzoyl peroxide dispersion, clindamycin or pharmaceutically acceptable salts or esters thereof, and a pharmaceutically acceptable carrier.

2004004, Mar 4, 2004

Jul 11, 2003

10/617191

Karl Popp - Schodack Landing NY, US

A61K031/704, A61K031/192

514/035000, 514/568000

Topical compositions and methods of using same for treating skin disorders or conditions comprising a storage-stable mixture of a benzoyl peroxide dispersion, clindamycin or pharmaceutically acceptable salts or esters thereof, and a pharmaceutically acceptable carrier.

2004018, Sep 23, 2004

Mar 1, 2004

10/790648

Karl Popp - Schodack Landing NY, US
Kathleen Clark - Medusa NY, US

A61K007/42, A61K007/135

424/059000, 424/062000

A composition for treatment of hyperpigmentation having a SPF value of at least 15 includes hydroquinone, sunscreens, antioxidants and emulsifiers and emollients. The composition can be made into an emulsion having physical and chemical stability for a prolonged period of time over a wide range of temperatures.

2004017, Sep 2, 2004

Mar 4, 2004

10/791862

Karl Popp - Schodack Landing NY, US

A61K031/704, A61K031/19

514/036000, 514/568000

Methods of using a topical composition comprising a storage-stable mixture of a benzoyl peroxide dispersion and clindamycin or pharmaceutically acceptable salts or esters thereof for treating rosacea. These methods also contemplate the reduction or elimination of organisms from affected skin areas, thereby reducing clinical signs of rosacea potentially due to allergic and vasomotor responses of the body to the organism in susceptible persons.

2005010, May 12, 2005

Nov 7, 2003

10/702782

Karl Popp - Schodack Landing NY, US
Ronald Santelli - Newark NY, US

A61K031/17, A61K035/78

424776000, 514588000

Topical dermatological compositions comprising urea as an active ingredient, a vegetable oil or a derivative thereof, water, and conventional excipients. These compositions are used for topical medical applications, particularly to treat various skin disorders.